%PDF-1.4
%
44 0 obj
<>
endobj
41 0 obj
<>
endobj
99 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2005-03-01T11:53:42Z
2024-03-28T02:54:17-07:00
QuarkXPressª: AdobePS 8.8.0 (301)
2024-03-28T02:54:17-07:00
application/pdf
Heather
2003-967.apr
uuid:d3abf40b-1dd1-11b2-0a00-9508271d5700
uuid:d3abf40d-1dd1-11b2-0a00-bf0000000000
endstream
endobj
30 0 obj
<>
endobj
31 0 obj
<>
endobj
45 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 16 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 18 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 20 0 R/Type/Page>>
endobj
7 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 22 0 R/Type/Page>>
endobj
10 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 24 0 R/Type/Page>>
endobj
117 0 obj
[121 0 R]
endobj
118 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
13.5 787.5 585 -783 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 60.468 737.0293 Tm
[(6.)-875.1 (Castro )17.7 (TC, )17.7 (T)69.9 (erreri MT)73.9 (, Szejnfeld )17.7 (VL, Castro CH, Fisber)17.7 (g M, Gabay)]TJ
1.675 -1.25 Td
(M. Bone mineral density in juvenile systemic lupus )Tj
0 -1.25 TD
[(erythematosus. Braz J Med Biol Res 2002;35:1)36.8 (159-63.)]TJ
-1.675 -1.25 Td
[(7.)-875.1 (Brik R, Keidar Z, Schapira D, Israel O. Bone mineral density and)]TJ
1.675 -1.25 Td
(turnover in children with systemic juvenile chronic arthritis. )Tj
T*
(J Rheumatol 1998;25:990-2.)Tj
-1.675 -1.25 Td
[(8.)-875.1 (Hopp R, Degan J, Gallagher JC, Cassidy JT)73.9 (. Estimation of bone)]TJ
1.675 -1.25 Td
(mineral density in children with juvenile rheumatoid arthritis. )Tj
T*
(J Rheumatology 1991;18:1235-9.)Tj
-1.675 -1.25 Td
[(9.)-875.1 (Falcini F)79.7 (,)-0.1 ( )17.7 (T)35 (rapani S, Civinini R, Capone )54.8 (A, Ermini M, Bartolozzi)]TJ
1.675 -1.25 Td
[(G. )17.7 (The primary role of steroids on the osteoporosis in juvenile)]TJ
T*
[(rheumatoid patients evaluated by dual ener)17.7 (gy X-ray absorptiometry)64.8 (.)]TJ
T*
(J Endocrinol Invest 1996;19:165-9.)Tj
-2.175 -1.25 Td
[(10.)-875.1 (Pepmueller PH, Cassidy JT)73.9 (, )54.8 (Allen SH, Hillman LS. Bone )]TJ
2.175 -1.25 Td
(mineralization and bone mineral metabolism in children with )Tj
T*
[(juvenile rheumatoid arthritis. )54.8 (Arthritis Rheum 1996;39:746-57.)]TJ
-2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Elsasser U, )17.7 (W)39.8 (ilkins B, Hesp R, )17.7 (Thurnham DI, Reeve J, )54.8 (Ansell BM.)]TJ
2.1381 -1.25 Td
(Bone rarefaction and crush fractures in juvenile chronic arthritis.)Tj
T*
(Arch Dis Child 1982;57:377-80.)Tj
-2.175 -1.25 Td
[(12.)-875.1 (Stewart )17.7 (W)110.9 (A, )54.8 (Acott PD, Salisbury SR, Lang BA. Bone mineral )]TJ
2.175 -1.25 Td
[(density in juvenile dermatomyositis: )54.8 (Assessment using dual x-ray)]TJ
T*
[(absorptiometry)64.8 (. )54.8 (Arthritis Rheum 2003;48:2294-8.)]TJ
-2.175 -1.25 Td
[(13.)-875.1 (Perez MD, )54.8 (Abrams SA, Koenning G, Stuf)17.7 (f JE, O\325Brien KO, Ellis)]TJ
2.175 -1.25 Td
(KJ. Mineral metabolism in children with dermatomyositis. )Tj
T*
(J Rheumatol 1994;21:2364-9.)Tj
-2.175 -1.25 Td
[(14.)-875.1 (Mul D, van Suijlekom-Smit L)73.9 (W)91.8 (, ten Cate R, Bekkering )17.7 (WP)110.7 (, de)]TJ
2.175 -1.25 Td
[(Muinck Keizer)19.7 (-Schrama SM. Bone mineral density and body )]TJ
T*
(composition and influencing factors in children with rheumatic )Tj
T*
(diseases treated with corticosteroids. J Pediatr Endocrinol Metab)Tj
0 Tc 0 Tw T*
(2002;15:187-92.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(15.)-875.1 (Falcini F)79.7 (, Bindi G, Ermini M, et al. Comparison of quantitative )]TJ
2.175 -1.25 Td
[(calcaneal ultrasound and dual ener)17.7 (gy X-ray absorptiometry in the)]TJ
T*
(evaluation of osteoporotic risk in children with chronic rheumatic)Tj
T*
[(diseases. Calcif )17.7 (T)35 (issue Int 2000;67:19-23.)]TJ
-2.175 -1.25 Td
[(16.)-875.1 (Lu PW)91.7 (, Briody JN, Ogle GD, et al. Bone mineral density of total)]TJ
2.175 -1.25 Td
[(body)64.8 (, spine, and femoral neck in children and young adults: a cross-)]TJ
T*
[(sectional and longitudinal study)64.8 (. J Bone Miner Res 1994;9:1451-8.)]TJ
-2.175 -1.25 Td
[(17.)-875.1 (W)79.9 (ang MC, )54.8 (Aguirre M, Bhudhikanok GS, et al. Bone mass and hip)]TJ
2.175 -1.25 Td
[(axis length in healthy )54.8 (Asian, Black, Hispanic, and )17.7 (White )54.8 (American)]TJ
0 Tc T*
(youths. J Bone Miner Res 1997;12:1922-35.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(18.)-875.1 (Dykman )17.8 (TR, Gluck OS, Murphy )17.8 (W)110.9 (A, Hahn )17.8 (TJ, Hahn BH.)]TJ
2.175 -1.25 Td
(Evaluation of factors associated with glucocorticoid-induced)Tj
T*
[(osteopenia in patients with rheumatic diseases. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(1985;28:361-8.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(19.)-875.1 (Hansen M, Halber)17.7 (g P)110.8 (, Kollerup G, et al. Bone metabolism in)]TJ
2.175 -1.25 Td
[(patients with systemic lupus erythematosus. Ef)17.7 (fect of disease )]TJ
T*
(activity and glucocorticoid treatment. Scand J Rheumatol)Tj
0 Tc 0 Tw T*
(1998;27:197-206.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(20.)-875.1 (Kipen )36.8 (Y)128.9 (, Buchbinder R, Forbes )54.8 (A, Strauss B, Littlejohn G, Morand)]TJ
2.175 -1.25 Td
(E. Prevalence of reduced bone mineral density in systemic lupus)Tj
T*
(erythematosus and the role of steroids. J Rheumatol )Tj
0 Tc 0 Tw T*
(1997;24:1922-9.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(21.)-875.1 (Pons F)79.7 (, Peris P)110.7 (, Guanabens N, et al. )17.7 (The ef)17.7 (fect of systemic lupus)]TJ
2.175 -1.25 Td
(erythematosus and long-term steroid therapy on bone mass in )Tj
T*
(pre-menopausal women. Br J Rheumatol 1995;34:742-6.)Tj
-2.175 -1.25 Td
[(22.)-875.1 (Lakshminarayanan S, )17.7 (W)79.9 (alsh S, Mohanraj M, Rothfield N. Factors)]TJ
2.175 -1.25 Td
(associated with low bone mineral density in female patients with)Tj
T*
(systemic lupus erythematosus. J Rheumatol 2001;28:102-8.)Tj
-2.175 -1.25 Td
[(23.)-875.1 (T)69.9 (an EM, Cohen )54.8 (AS, Fries JF)79.7 (, et al. )17.7 (The 1982 revised criteria for the)]TJ
2.175 -1.25 Td
[(classification of systemic lupus erythematosus. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(1982;25:1271-7.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(24.)-875.1 (Baker SS, Cochran )17.7 (WJ, Flores CA, et al. )54.8 (American )54.8 (Academy of)]TJ
2.175 -1.25 Td
(Pediatrics Committee on Nutrition. Calcium requirements of)Tj
T*
[(infants, children, and adolescents. Pediatrics 1999;104:1)36.8 (152-7.)]TJ
30.8875 78.75 Td
[(25.)-875.1 (Crocker PR, Bailey DA, Faulkner RA, Kowalski KC, McGrath R.)]TJ
2.175 -1.25 Td
(Measuring general levels of physical activity: preliminary evidence)Tj
T*
[(for the Physical )54.8 (Activity Questionnaire for Older Children. Med Sci)]TJ
T*
(Sports Exerc 1997;29:1344-9.)Tj
-2.175 -1.25 Td
[(26.)-875.1 (Duke PM, Litt IF)79.7 (, Gross R)59.7 (T)74 (. )54.8 (Adolescents\325)-201.1 (self-assessment of sexual)]TJ
2.175 -1.25 Td
(maturation. Pediatrics 1980;66:918-20.)Tj
-2.175 -1.25 Td
[(27.)-875.1 (T)69.9 (anner JM. Foetus into man: physical growth from conception to)]TJ
2.175 -1.25 Td
[(maturity)64.8 (. Cambridge, MA: Harvard University Press; 1978:197-9.)]TJ
-2.175 -1.25 Td
[(28.)-875.1 (Johnston CC Jr)39.7 (, Slemenda CW)91.7 (, Melton LJ 3rd. Clinical use of bone)]TJ
0 Tc 2.175 -1.25 Td
[(densitometry)64.9 (. N Engl J Med 1991;324:1)36.9 (105-9.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(29.)-875.1 (Kanis JA. )54.8 (Assessment of fracture risk and its application to )]TJ
2.175 -1.25 Td
[(screening for postmenopausal osteoporosis: synopsis of a )17.7 (WHO)]TJ
T*
[(report. )17.7 (WHO Study Group. Osteoporosis Int 1994;4:368-81.)]TJ
-2.175 -1.25 Td
[(30.)-875.1 (Cunnane G, Lane NE. Steroid-induced osteoporosis in systemic)]TJ
2.175 -1.25 Td
[(lupus erythematosus. Rheum Dis Clin North )54.8 (Am 2000;26:31)36.8 (1-29.)]TJ
-2.175 -1.25 Td
[(31.)-875.1 (Swaak )54.8 (AJ, van den Brink HG, Smeenk RJ, Manger K, Kalden JR.)]TJ
2.175 -1.25 Td
(Systemic lupus erythematosus: clinical features in patients with )Tj
T*
(disease duration of over 10 years, first evaluation. Rheumatology)Tj
T*
(Oxford 1999;38:953-8.)Tj
-2.175 -1.25 Td
[(32.)-875.1 (Dhillon )17.6 (VB, Davies MC, Hall ML, et al. )54.7 (Assessment of the ef)17.7 (fect of)]TJ
2.175 -1.25 Td
(oral corticosteroids on bone mineral density in systemic lupus )Tj
T*
[(erythematosus: a preliminary study with dual ener)17.7 (gy x-ray )]TJ
0 Tc T*
[(absorptiometry)64.9 (. )54.9 (Ann Rheum Dis 1990;49:624-6.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(33.)-875.1 (Formiga F)79.7 (, Moga I, Nolla JM, Pac M, Mitjavila F)79.7 (, Roig-Escofet D.)]TJ
2.175 -1.25 Td
(Loss of bone mineral density in premenopausal women with )Tj
T*
[(systemic lupus erythematosus. )54.8 (Ann Rheum Dis 1995;54:274-6.)]TJ
-2.175 -1.25 Td
[(34.)-875.1 (Johnston CC Jr)39.7 (, Miller JZ, Slemenda CW)91.7 (, et al. Calcium )]TJ
2.175 -1.25 Td
(supplementation and increases in bone mineral density in children.)Tj
0 Tc T*
(N Engl J Med 1992;327:82-7.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(35.)-875.1 (W)79.9 (arady BD, Lindsley CB, Robinson FG, Lukert BP)110.7 (. Ef)17.7 (fects of)]TJ
2.175 -1.25 Td
(nutritional supplementation on bone mineral status of children with)Tj
T*
[(rheumatic diseases receiving corticosteroid therapy)64.8 (. J Rheumatol)]TJ
0 Tc 0 Tw T*
(1994;21:530-5.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(36.)-875.1 (Reed )54.8 (A, Haugen M, Pachman LM, Langman CB. 25-)]TJ
2.175 -1.25 Td
(Hydroxyvitamin D therapy in children with active juvenile )Tj
T*
[(rheumatoid arthritis: short-term ef)17.7 (fects on serum osteocalcin levels)]TJ
T*
[(and bone mineral density)64.8 (. J Pediatr 1991;1)36.8 (19:657-60.)]TJ
-2.175 -1.25 Td
[(37.)-875.1 (Morris FL, Naughton GA, Gibbs JL, Carlson JS, )17.7 (W)79.9 (ark JD.)]TJ
2.175 -1.25 Td
(Prospective ten-month exercise intervention in premenarcheal girls:)Tj
T*
[(positive ef)17.7 (fects on bone and lean mass. J Bone Miner Res)]TJ
0 Tc 0 Tw T*
(1997;12:1453-62.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(38.)-875.1 (Bradney M, Pearce G, Naughton G, et al. Moderate exercise during)]TJ
2.175 -1.25 Td
(growth in prepubertal boys: changes in bone mass, size, volumetric)Tj
T*
[(density)64.8 (, and bone strength: a controlled prospective study)64.8 (. J Bone)]TJ
T*
(Miner Res 1998;13:1814-21.)Tj
-2.175 -1.25 Td
[(39.)-875.1 (Mackelvie KJ, McKay HA, Khan KM, Crocker PR. Lifestyle risk)]TJ
2.175 -1.25 Td
[(factors for osteoporosis in )54.8 (Asian and Caucasian girls. Med Sci)]TJ
T*
(Sports Exerc 2001;33:1818-24.)Tj
-2.175 -1.25 Td
[(40.)-875.1 (Boot )54.8 (AM, De Ridder MA, Pols HA, Krenning EP)110.7 (, de Muinck)]TJ
2.175 -1.25 Td
[(Keizer)19.7 (-Schrama SM. Bone mineral density in children and )]TJ
T*
[(adolescents: Relation to puberty)64.8 (, calcium intake, and physical )]TJ
T*
[(activity)64.9 (. J Clin Endocrinol Metab 1997;82:57-62.)]TJ
-2.175 -1.25 Td
[(41.)-875.1 (Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH,)]TJ
2.175 -1.25 Td
(and the Committee on Prognosis Studies in SLE. Derivation of the)Tj
T*
[(SLEDAI. )54.8 (A)-220.1 (disease activity index for lupus patients. )54.8 (Arthritis)]TJ
0 Tc T*
(Rheum 1992;35:630-40.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(42.)-875.1 (Cimaz R, Gattorno M, Sormani MP)110.7 (, et al. Changes in markers of)]TJ
2.175 -1.25 Td
(bone turnover and inflammatory variables during alendronate )Tj
T*
(therapy in pediatric patients with rheumatic diseases. J Rheumatol)Tj
0 Tc 0 Tw T*
(2002;29:1786-92.)Tj
ET
0 0 0 1 K
53.468 76.5 m
558.468 76.5 l
S
0 0 0 0 k
494.29 69.365 64.178 -15.665 re
f*
BT
0 0 0 1 k
/T1_1 1 Tf
8 0 0 8 545.468 56.4344 Tm
(733)Tj
ET
0 0 0 0 k
53.532 70.406 203 -16.841 re
f*
BT
0 0 0 1 k
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 54.532 56.2997 Tm
(Alsufyani, et al: BMD in pediatric disease)Tj
ET
0 0 0 0 k
/GS0 gs
103.631 81.583 407.5 -10.833 re
f*
0.5 w
/GS1 gs
103.631 81.583 407.5 -10.833 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_2 8 Tf
108.828 74 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2005. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_3 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
24 0 obj
<>stream
8;Z\6$Wb2"#itt$b]VEPk,$g2_Z@=]aU:)UrgQWp?jnb#CBlgiX:9,de@434'7(_M!]hsXiYB]Jmk;ces0qg
CGl7rZDPY9iSetk*PEK/.(CA/t/,KFXt]5"mRbk_BP#a$:2X1RoYgK>Nf3@&p!
>7XO;6kIB@S\Mn6h)h/MLUR+A2&Ti6CLg0)SPchNH@#qgH$l!,q4VDJ>dOcZ#inBh
QZd7'Bh;4>.S8):6l#"6*!uq7/Pq?c\l?o99l(=0b3&.dU2R+Q&!/,pL=-o?,#ooC
\jFV%T]+VrFKn[$-:>:^2%%71^?'m(^eY<-d5J!^Zfn\@S6EIFi*fpe&_pU7?uhG*
P)7#+CKM-a'0&_\Xg
endstream
endobj
28 0 obj
[/Indexed/DeviceRGB 255 27 0 R]
endobj
27 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
58 0 obj
<>
endobj
47 0 obj
<>
endobj
88 0 obj
<>
endobj
104 0 obj
<>
endobj
48 0 obj
<>
endobj
81 0 obj
<>stream
H|UiPIꦪF,j*VP5FQ@TTcm9FKEXGDmksg5uaFY 1`5F!M~Șy5jPiԆ^ϯ&R3> W'x31jjVcKQ>KIl=6ļ|Ö˱5X:L'ƾ4C"HHlfؔ"hb'dJJ^g;6]Q{(o'%L:Gc+'?hJ2AL:usMPN0Q&+xQLs ZO5!vzO
0b5}LGħ
،te@z;80}uvlX+rjgN
BѼ3hkh"_:!)B'
,
8aj ز KD'7!`rhoK+M!Rhh#'|HJll